Advanced Filters
noise

A, Concord N Clinical Trials

A listing of A, Concord N clinical trials actively recruiting patients volunteers.

Found 11,315 clinical trials

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

18 years of age All Phase 3
L Lélia ESCAUT, Dr

Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions

This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored …

18 years of age All Phase N/A
A Ajay Goel, PhD

A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay for accurate detection of early-stage HCC.

18 years of age All Phase N/A

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

The purpose of this study is to: Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

40 - 80 years of age All Phase 1
T TZU-TING CHEN

Development of a Clinical Skills Teaching Video Database in Occupational Therapy

This study aims to develop a video and audio database for teaching and learning clinical skills in occupational therapy. The database will include recordings of clinical teaching sessions, skill demonstrations, student practice, and interactions between occupational therapists, trainees, and patients or family members. Participants may include occupational therapists involved in …

years of age All Phase N/A
T Tim Poterucha, M.D.

A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV/RV size and function, valvular disease severity) and stratifying disease progression risk. The primary outcome is clinician usability, interpretive consistency, and workflow integration. Second, we will conduct …

18 years of age All Phase N/A
C Chidi Asuzu

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

18 - 100 years of age All Phase 2

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Clinical Study on the efficacy and safety of HAIC(GEMOX)and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.

18 - 75 years of age All Phase 3
J Joint Research

Mobility and Activity of Daily Living Outcomes After a Hip Fracture.

Hip fractures in especially older adults cause severe clinical and functional impacts. Despite improved surgical care, one year mortality remains 14-30%, and fewer than half of the survivors regain their pre-fracture functional status. After a hip fracture, patients are primarily concerned with what they will be able to do in …

18 years of age All Phase N/A
L Laurie Jarvis

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of …

18 - 60 years of age All Phase 3

Simplify language using AI